Genetics of Pancreatic Cancer and Its Implications on Therapy

Talar Tatarian; Jordan M Winter

doi:10.1016/j.suc.2016.07.014

Genetics of Pancreatic Cancer and Its Implications on Therapy

Surg Clin North Am. 2016 Dec;96(6):1207-1221. doi: 10.1016/j.suc.2016.07.014.

Authors

Talar Tatarian¹, Jordan M Winter²

Affiliations

¹ Department of Surgery, The Jefferson Pancreas, Biliary and Related Cancer Center, Sidney Kimmel Medical College, Thomas Jefferson University Hospital, 1015 Walnut Street, Suite 620, Philadelphia, PA 19107, USA.
² Department of Surgery, The Jefferson Pancreas, Biliary and Related Cancer Center, Sidney Kimmel Medical College, Thomas Jefferson University, 1025 Walnut Street, Suite 605, Philadelphia, PA 19107, USA. Electronic address: Jordan.Winter@jefferson.edu.

PMID: 27865273
DOI: 10.1016/j.suc.2016.07.014

Abstract

Over the past decade, emerging technologies have provided new insights into the genomic landscape of pancreatic ductal adenocarcinoma (PDA). In addition to the commonly recognized genetic drivers of pancreatic carcinogenesis (KRAS, CDKN2A, TP53, SMAD4), new genes and pathways have been implicated. However, these efforts have not identified any new high-frequency actionable mutations, limiting the success of mutation-targeted therapy in PDA. This article provides a report on the current landscape of pancreas cancer genetics and targeted therapeutics.

Keywords: Genetics; Pancreatic cancer; Personalized medicine; Targeted therapy.

Publication types

Review

MeSH terms

Combined Modality Therapy
Disease Management*
Genes, Neoplasm / genetics*
Humans
Pancreatic Neoplasms / genetics*
Pancreatic Neoplasms / therapy*